ESMO open · 2026
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cabel L, Lamy C, Abbott C W, Keough K C, Pouget N, Pierga J-Y, Sablin M-P, Flavius J, Bronzini T, Laas E, Darrigues L, Li B, Navarro F C P, Féron J-G, Fourchotte V, Bonneau C, Vincent-Salomon A, Boyle S M, Chen R O, Le Tourneau C, Bidard F-C
Аннотация
BACKGROUND: Current treatment guidelines for patients diagnosed with stage II to III triple-negative breast cancer (TNBC) rely on the use of neoadjuvant therapy (NAT). A critical unmet need is a sensitive test that can inform the presence of distant micrometastases to help personalize postneoadjuvant systemic therapy beyond pathological complete response (pCR).
PATIENTS AND METHODS: In this study, 286 plasma samples from 86 patients from the SCANDARE study were retrospectively analyzed for circulating tumor DNA (ctDNA) at three presurgical timepoints: baseline, during and post-NAT, and during postsurgical follow-up, when available, using an ultrasensitive, tumor-informed, whole-genome-based assay.
RESULTS: After a median follow-up of 5.1 years, 15 patients (17.4%) had developed distant metastases, and 19 patients (22.1%) died; 100% of pretreatment baseline plasma samples were positive for detected ctDNA, and the majority of ctDNA detections during and post-NAT, presurgery, were at ultrasensitive (<100 parts per million) levels. Ultrasensitive ctDNA detection post-NAT, presurgery was highly prognostic of distant recurrence-free interval, disease-free survival, and overall survival. Notably, ultrasensitive ctDNA detection status improved the prognostication of patients without pCR at surgery, with 94% of non-pCR patients with undetectable ctDNA post-NAT, presurgery remaining distant recurrence-free.
CONCLUSIONS: These findings highlight the potential of ctDNA to refine risk assessment in patients with early-stage TNBC and support its investigation in interventional settings to guide systemic treatment decisions.
PATIENTS AND METHODS: In this study, 286 plasma samples from 86 patients from the SCANDARE study were retrospectively analyzed for circulating tumor DNA (ctDNA) at three presurgical timepoints: baseline, during and post-NAT, and during postsurgical follow-up, when available, using an ultrasensitive, tumor-informed, whole-genome-based assay.
RESULTS: After a median follow-up of 5.1 years, 15 patients (17.4%) had developed distant metastases, and 19 patients (22.1%) died; 100% of pretreatment baseline plasma samples were positive for detected ctDNA, and the majority of ctDNA detections during and post-NAT, presurgery, were at ultrasensitive (<100 parts per million) levels. Ultrasensitive ctDNA detection post-NAT, presurgery was highly prognostic of distant recurrence-free interval, disease-free survival, and overall survival. Notably, ultrasensitive ctDNA detection status improved the prognostication of patients without pCR at surgery, with 94% of non-pCR patients with undetectable ctDNA post-NAT, presurgery remaining distant recurrence-free.
CONCLUSIONS: These findings highlight the potential of ctDNA to refine risk assessment in patients with early-stage TNBC and support its investigation in interventional settings to guide systemic treatment decisions.